Requirement of c-jun for testosterone-induced sensitization to N-(4-hydroxyphenyl)-retinamide-induced apoptosis

Molecular Carcinogenesis

Volumn 36, Issue 3, 2003, Pages 115-122

  Shimada, Keiji ^a   Nakamura, Mitsutoshi ^a   Ishida, Eiwa ^a   Kishi, Munehiro ^a   Konishi, Noboru ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

c jun; Extracellular signal regulated kinase; N (4 hydroxyphenyl)retinamide; Testosterone

Indexed keywords

ANDROGEN; FENRETINIDE; STRESS ACTIVATED PROTEIN KINASE; TESTOSTERONE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; ENZYME ACTIVATION; HORMONE ACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIZATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ENZYME INHIBITORS; FENRETINIDE; FLAVONOIDS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TESTOSTERONE; TUMOR CELLS, CULTURED;

EID: 0037335551     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.10107     Document Type: Article

References (32)

1. Costa A, De Palo G, Decensi A, et al. Retinoids in cancer chemoprevention: Clinical trials with the synthetic analogue fenretinide. Ann NY Acad Sci 1995;768:148-162.
2. Roberson KM, Penland SN, Padilla GM, et al. Fenretinide: Induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells. Cell Growth Differ 1997;8:101-111.
3. Man T. Solid tumours-chemoprevention with retinoids. Leukemia 1994;8:1785-1790.
4. Formelli F, Clerici M, Campa T, et al. Five-year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993;11:2036-2042.
5. Pienta KJ, Esper PS, Zwas F, Krzeminski R, Flaherty LE. Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate. Am J Clin Oncol 1997; 20:36-39.
6. Konishi N, Cho M, Yamamoto K, Hiasa Y. Genetic changes in prostate cancer. Pathol Int 1997;47:735-747.
7. Sun SY, Li W, Yue P, Lippman SM, Hong WK, Lotan R. Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res 1999;59:2493-2498.
8. Shimada K, Nakamura M, Ishida E, Kishi M, Yonehara S, Konishi N. Contributions of mitogen-activated protein kinase and nuclear factor kappa B to N-(4-hydroxyphenyl)-retinamide-induced apoptosis in prostate cancer cells. Mol Carcinog 2002;35:127-137.
9. Collins SJ. The role of retinoids and retinoic acid receptors in normal hematopoiesis. Leukemia 2002;16:1896-1905.
10. Fontana JA, Rishi AK. Classical and novel retinoids: Their targets in cancer therapy. Leukemia 2002;16:463-472.
11. Cunha GR, Donjacour AA, Cooke PS, et al. The endocrinology and developmental biology of the prostate. Endocr Rev 1987;8:338-362.
12. Peterziel H, Mink S, Schonert A, Becker M, Klocker H, Cato AC. Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 1999;18:6322-6329.
13. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001;93:1687-1697.
14. Kimura K, Markowski M, Bowen C, Gelmann EP. Androgen blocks apoptosis of hormone-dependent prostate cancer cells. Cancer Res 2001;61:5611-5618.
15. Shen JC, Wang TT, Chang S, Hursting SD. Mechanistic studies of the effects of the retinoid N-(4-hydroxyphenyl)-retinamide on prostate cancer cell growth and apoptosis. Mol Carcinog 1999;24:160-168.
16. Moriguchi T, Toyoshima F, Masuyama N, Hanafusa H, Gotoh Y, Nishida E. A novel SAPK/JNK kinase, MKK7, stimulated by TNFalpha and cellular stresses. Embo J 1997;16:7045-7053.
17. Takeshita A, Watanabe A, Takada Y, Hanazawa S. Selective stimulation by ceramide of the expression of the alpha isoform of retinoic acid and retinoid X receptors in osteoblastic cells: A role of sphingosine 1-phosphate-mediated AP-1 in the ligand-dependent transcriptional activity of these receptors. J Biol Chem 2000;275:32220-32226.
18. Kondo T, Matsuda T, Kitano T, et al. Role of c-jun expression increased by heat shock- and ceramide-activated caspase-3 in HL-60 cell apoptosis. Possible involvement of ceramide in heat shock-induced apoptosis. J Biol Chem 2000;275:7668-7676.
19. Toyoshima F, Moriguchi T, Nishida E. Fas induces cytoplasmic apoptotic responses and activation of the MKK7-JNK/SAPK and MKK6-p38 pathways independent of CPP32-like proteases. J Cell Biol 1997;139:1005-1015.
20. Karin M.The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995;270:16483-16486.
21. Lee W, Mitchell P, Tjian R. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell 1987; 49:741-752.
22. Chen YR, Zhou G, Tan TH. c-Jun N-terminal kinase mediates apoptotic signaling induced by N-(4-hydroxyphenyl)retinamide. Mol Pharmacol 1999;56:1271-1279.
23. Engedal N, Korkmaz CG, Saatcioglu F. C-Jun N-terminal kinase is required for phorbol ester- and thapsigargininduced apoptosis in the androgen responsive prostate cancer cell line LNCaP. Oncogene 2002;21:1017-1027.
24. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001;20:2390-2400.
25. Angel P, Hattori K, Smeal T, Karin M. The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 1988;55:875-885.
26. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991;1072:129-157.
27. Yang DD, Kuan CY, Whitmarsh AJ. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 1997;389:865-870.
28. Verheij M, Bose R, Lin XH, et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996;380:75-79.
29. Shaulian E, Schreiber M, Piu F, Beeche M, Wagner EF, Karin M. The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest. Cell 2000;103: 897-907.
30. Tournier C, Hess P, Yang DD, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000;288:870-874.
31. Kolbus A, Herr I, Schreiber M, Debatin KM, Wagner EF, Angel P. c-Jun-dependent CD95-L expression is a rate-limiting step in the induction of apoptosis by alkylating agents. Mol Cell Biol 2000;20:575-582.
32. Wisdom R, Johnson RS, Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. Embo J 1999;18:188-197.